Objective: To describe a case of azathioprine hypersensitivity in a patient with ulcerative colitis.
Case Summary: A 40-year-old white man with ulcerative colitis, treated with chronic mesalamine and occasional steroids, was admitted to the hospital with a 3-day history of fever, nausea, vomiting, and a rash. Fourteen days prior to admission, the patient had been started on azathioprine for ulcerative colitis. Upon admission, azathioprine therapy was temporarily withheld, resulting in resolution of his signs and symptoms. Symptoms returned when azathioprine was restarted. It was decided that these signs and symptoms were most likely caused by azathioprine hypersensitivity, and the agent was discontinued.
Discussion: To our knowledge, this is the first reported case of azathioprine hypersensitivity in a patient with ulcerative colitis. The time course and presenting signs and symptoms support the diagnosis of azathioprine hypersensitivity, as does the patient's response to rechallenge. The mechanism of this hypersensitivity reaction is unclear, but may involve the nitroimidazole portion of the azathioprine molecule.
Conclusions: Azathioprine hypersensitivity often presents with signs and symptoms resembling a systemic infection such as fever, leukocytosis, and evidence of end organ dysfunction. The diagnosis of azathioprine hypersensitivity should be considered in patients who have recently either initiated or increased their dosage of azathioprine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1345/aph.17395 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunosuppressants in dermatology on vaccine immunogenicity: a prospective cohort study of pemphigus patients in the pandemic.
Front Immunol
December 2024
Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Keelung, Taiwan.
Introduction: Both cellular and humoral responses are important for vaccine protection, but recommendations on immunosuppressants in dermatology are largely based on pre-pandemic experiences. This study aimed to investigate the impacts of immunosuppressants on humoral and cellular immunogenicity to COVID-19 vaccinations in pemphigus patients.
Methods: SARS-CoV-2-naïve pemphigus patients and age-, and sex-matched healthy controls were recruited from multiple tertiary medical centers during 2021-2023.
Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network.
J Dermatolog Treat
December 2024
Institute and Comprehensive Center for Inflammation Medicine, University-Hospital Lübeck, Lübeck, Germany.
Article Synopsis
- The study analyzed the long-term safety of dupilumab, a drug for atopic dermatitis (AD), compared to conventional systemic treatments like azathioprine and methotrexate using electronic health records.
- Findings showed that dupilumab had a lower risk of various adverse effects, including infections and type 2 inflammatory diseases, compared to other treatments.
- However, the risk of conjunctivitis was higher in patients treated with dupilumab compared to those on mycophenolate mofetil and methotrexate, prompting the need for further research to confirm these results.
Successful novel use of dupilumab for gastrointestinal involvement of idiopathic hypereosinophilic syndrome: case report and review of the literature.
Clin J Gastroenterol
December 2024
Celiac Disease Program, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Article Synopsis
- Hypereosinophilic syndrome (HES) leads to high levels of eosinophils in the blood and tissues, causing organ damage, with gastrointestinal issues being a common manifestation.
- A 28-year-old female patient suffered from severe gastrointestinal symptoms and was diagnosed with idiopathic HES and eosinophilic esophagitis, resistant to multiple treatments.
- After starting dupilumab, a recently FDA-approved treatment, the patient achieved remission, resolving her gastrointestinal issues and allowing her to return to a normal diet without needing total parenteral nutrition.
Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study.
Allergy
October 2024
Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Article Synopsis
- Dupilumab is a biologic medication approved for treating atopic dermatitis in kids aged 6 months to 17 years, and the study focused on its effects on associated health issues in these patients.* -
- Using electronic health records, researchers matched 3,575 pediatric patients receiving dupilumab with the same number receiving other treatments, assessing the emergence of new health problems.* -
- Results showed that dupilumab significantly reduced the risk of various comorbidities like asthma, infections, and psychiatric disorders, especially in younger children (0-5 years).*
A case report of reversible left ventricular dysfunction due to azathioprine hypersensitivity syndrome.
Eur Heart J Case Rep
August 2024
Cardiology Department, Kantonsspital St. Gallen, Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland.
Background: Hypersensitivity reaction is a rare side effect during immunosuppressive treatment with azathioprine (AZA). Some cases of cardiac involvement have already been reported but causality is notoriously difficult to prove.
Case Summary: We present the case of a 68-year-old man with two episodes of reversible left ventricular (LV) dysfunction.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!